The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19

Y. Belenkov, I. Menshikova, I. Ilgisonis, Yu. I. Naimann, Y. Pak, I. Kolosova, A. S. Rakovskaya
{"title":"The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19","authors":"Y. Belenkov, I. Menshikova, I. Ilgisonis, Yu. I. Naimann, Y. Pak, I. Kolosova, A. S. Rakovskaya","doi":"10.47093/2218-7332.2020.11.2.29-39","DOIUrl":null,"url":null,"abstract":"Hydroxychloroquine (HCH) is included in guidelines for treatment of novel coronavirus infection (COVID-19). Data on increased risk of cardiovascular complications when using it have been published. Aim. To evaluate the safety and tolerability of HCH and azithromycine (AZM) combination for the treatment of the patients with COVID-19 in recommended by Russian Ministry of Health doses in real practice.Methods. 132 patients (62 men and 70 women of average age 59.2 ± 9.3 years), 59% of whom had cardiovascular comorbidities, were included in prospective сohort study. 112 patients took HCH + AZM (group 1) and 20 patients took other medications without potential cardiotoxicity (group 2). At the admission to the hospital and after 5–7 days of the treatment corrected QT interval was calculated, new rhythm and conduction disorders, other side effects and hospital mortality have been registering. Relative risk (RR) and 95% confidence interval (CI) were calculated. Results. Elongation of corrected QT-interval within the normal range was registered in 22.3% of patients in group 1 and in 15% — in group 2. An increase in the QT length to the upper limit of the norm (480 msec) was observed in 1.8% of patients in group 1. There were no statistically significant differences between the groups in the number of patients with prolonged QT interval (RR = 1.488, 95% CI: 0.496–4.466, р = 0.478). The occurrence of new arrhythmias, conduction disturbances and allergic reactions was not recorded. Tolerability of combination HCH + AZM was satisfactory in the majority of patients. The hospital mortality in group 1 was 1.8%, in group 2 — 5% without statistically significant difference (p = 0.374). Conclusion. A combination of HCL + AZM according to the scheme recommended by the Ministry of Health of the Russian Federation for the treatment of the patients with COVID-19 and cardiovascular comorbidity in inpatient conditions is safe.","PeriodicalId":129151,"journal":{"name":"Sechenov Medical Journal","volume":"33 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sechenov Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47093/2218-7332.2020.11.2.29-39","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hydroxychloroquine (HCH) is included in guidelines for treatment of novel coronavirus infection (COVID-19). Data on increased risk of cardiovascular complications when using it have been published. Aim. To evaluate the safety and tolerability of HCH and azithromycine (AZM) combination for the treatment of the patients with COVID-19 in recommended by Russian Ministry of Health doses in real practice.Methods. 132 patients (62 men and 70 women of average age 59.2 ± 9.3 years), 59% of whom had cardiovascular comorbidities, were included in prospective сohort study. 112 patients took HCH + AZM (group 1) and 20 patients took other medications without potential cardiotoxicity (group 2). At the admission to the hospital and after 5–7 days of the treatment corrected QT interval was calculated, new rhythm and conduction disorders, other side effects and hospital mortality have been registering. Relative risk (RR) and 95% confidence interval (CI) were calculated. Results. Elongation of corrected QT-interval within the normal range was registered in 22.3% of patients in group 1 and in 15% — in group 2. An increase in the QT length to the upper limit of the norm (480 msec) was observed in 1.8% of patients in group 1. There were no statistically significant differences between the groups in the number of patients with prolonged QT interval (RR = 1.488, 95% CI: 0.496–4.466, р = 0.478). The occurrence of new arrhythmias, conduction disturbances and allergic reactions was not recorded. Tolerability of combination HCH + AZM was satisfactory in the majority of patients. The hospital mortality in group 1 was 1.8%, in group 2 — 5% without statistically significant difference (p = 0.374). Conclusion. A combination of HCL + AZM according to the scheme recommended by the Ministry of Health of the Russian Federation for the treatment of the patients with COVID-19 and cardiovascular comorbidity in inpatient conditions is safe.
羟氯喹联合阿奇霉素对COVID-19住院患者心脏毒性的研究
羟氯喹(HCH)被列入新型冠状病毒感染(COVID-19)治疗指南。关于使用它时心血管并发症风险增加的数据已经公布。的目标。目的:评价俄罗斯卫生部推荐剂量下六氯环己烷与阿奇霉素(AZM)联合治疗新冠肺炎患者的安全性和耐受性。132例患者(男性62例,女性70例,平均年龄59.2±9.3岁),其中59%有心血管合并症,纳入前瞻性短期研究。112例患者服用HCH + AZM(第1组),20例患者服用其他无潜在心脏毒性的药物(第2组)。入院时和治疗5-7天后计算校正QT间期,记录新的节律和传导障碍、其他副作用和住院死亡率。计算相对危险度(RR)和95%置信区间(CI)。结果。校正后的qt间期在正常范围内的延长在第1组为22.3%,第2组为15%。第1组中1.8%的患者QT长度增加到标准的上限(480毫秒)。两组间QT间期延长患者数比较,差异无统计学意义(RR = 1.488, 95% CI: 0.496 ~ 4.466, r = 0.478)。无新发心律失常、传导障碍及过敏反应发生记录。大多数患者对HCH + AZM的耐受性满意。1组住院死亡率为1.8%,2组住院死亡率为5%,差异无统计学意义(p = 0.374)。结论。根据俄罗斯联邦卫生部推荐的方案,HCL + AZM联合治疗2019冠状病毒病和心血管合并症住院患者是安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信